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ABSTRACT 
The authors have recently reported equations, derived from a Nutrient Biomarker Study 
within the Women’s Health Initiative (WHI), that produce calibrated estimates of energy, 
protein, and % of energy from protein consumption estimates from corresponding food 
frequency questionnaire estimates and data on other factors, such as body mass index, 
age, and ethnicity.  Here these equations were applied to yield calibrated consumption 
estimates for 21,711 women enrolled in the WHI Dietary Modification trial comparison 
group, and 59,105 women enrolled in the Observational Study.  These estimates were 
related prospectively to the total and site-specific invasive cancer incidence.  In 
combined cohort analyses that do not control for body mass, uncalibrated energy was 
not associated with total cancer incidence or site-specific cancer incidence for most 
sites, whereas biomarker-calibrated energy was positively associated with total cancer 
(hazard ratio (HR) 1.18, 95% confidence interval (CI): 1.10, 1.27, for 20% consumption 
increase), as well with breast, colon, endometrial, and kidney cancer (respective HRs of 
1.24, 1.35, 1.83, and 1.47).  Calibrated protein was weakly associated, and calibrated % 
of energy from protein was inversely associated, with total cancer.  Calibrated energy 
and body mass index associations were highly interdependent.  Implications for the 
interpretation of nutritional epidemiology studies are described. 
 
Keywords: bias (epidemiology); biological markers; cancer incidence; diet; energy 
intake; epidemiologic methods; nutrition assessment; protein 
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Early international correlation studies reported a positive association between energy 
consumption and the incidence and mortality from cancer.  Among women, associations 
were reported for breast, colon, rectum, endometrium, ovary, and kidney cancer (1).  
Rodent feeding experiments indicate that underfeeding typically inhibits the 
development of site-specific and overall cancer (2, 3). 
 
Analytic epidemiologic studies of diet, nutrition, and cancer date to the 1970s.  Initial 
case-control studies used a range of dietary assessment procedures, including food 
records, recalls, and frequencies.  Concern about dietary recall bias subsequently led to 
cohort studies as the predominant design for dietary association studies.  Because 
these studies typically involve tens of thousands of enrollees, a self-administered, 
machine-readable food frequency questionnaire (FFQ) has been the principal dietary 
assessment tool in cohort studies. 
 
However, like other dietary assessment methods, the measurement properties of FFQs 
remain substantially unknown.  Comparison of FFQ assessments with food records 
reveals noteworthy differences (4) that imply an important error component to self-
reported nutrient intake.  Small-scale studies using a doubly-labeled water biomarker (5) 
of energy consumption suggest important systematic biases also, as obese persons 
may systematically underreport energy consumption (6) in some populations.  
Measurement error, especially systematic biases, may substantially distort diet and 
cancer associations.  It is important to examine nutrient and disease associations in a 
manner that appropriately accommodates FFQ measurement errors. 
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The accumulated data on diet and cancer were reviewed by an international panel of 
experts in 1997 (7).  Rather few ‘definite’ or ‘probable’ dietary associations emerged.  
The authors wrote, ‘the significance of the data on energy intake and cancer risk in 
humans remains unclear’ and ‘In the view of the panel, the effect of energy intake on 
cancer is best assessed by examining the factors:  rate of growth, body mass, and 
physical activity’.  This state of affairs has evidently not changed in the intervening 
decade (8), and reflects considerable uncertainty about energy consumption estimates 
and related association study findings.  The 1997 panel also assessed (7) that protein 
consumption was not ‘probably or convincingly’ related to the risk of any cancer.   
 
Good quality biomarkers of both total energy consumption (5) and protein consumption 
(9) have been developed, but for cost and logistics reasons have received little use in 
epidemiologic research.  These biomarkers involve urinary recovery of metabolites 
produced when these nutrients are expended.  In weight stable persons, they provide 
objective estimates of short-term energy and protein consumption.  The associated 
measurement error plausibly adheres to a simple classical measurement model 
W = Z + e      (A) 
where Z is the targeted (log-transformed) nutrient consumption, W is the (log-
transformed) biomarker measured consumption, and e is measurement error that is 
assumed to be independent of Z and of all other study subject characteristics.  The cost 
to ascertain these biomarkers for each participant in a cohort study would be excessive.  
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Instead, a substudy that includes both the biomarker and FFQ can be used to produce 
calibrated consumption estimates for all cohort members. 
 
The measurement model for the self-report data typically needs to be more complex 
than the classical measurement model (A):  Other factors such as body mass, ethnicity, 
and age, may affect the assessment, and measurement errors may be correlated if the 
assessment is repeated for specific study subjects.  Hence, we consider a 
measurement model (10, 11) 
Q = So + S1Z + S2V + S3VZ + r + u    (B) 
for the (log-transformed) self-report nutrient assessment Q, where V is a set of 
characteristics that may relate to systematic bias in the assessment, r is a person-
specific error variable that will be present in each self-report assessment for a study 
subject, u is an independent measurement error term.  Also, S0, S1, S2, and S3 are 
constants to be estimated, and all variables on the right sides of (A) and (B) are 
assumed to be independent, given V.   
 
We have recently reported FFQ measurement error findings from a Nutritional 
Biomarker Study (NBS) among 544 women enrolled in the WHI Dietary Modification 
(DM) trial (12).  FFQ estimates of energy, protein, and % of energy from protein were 
each found to incorporate important systematic bias, and corresponding calibration 
equations were developed.  Here we use these equations to produce calibrated 
estimates of energy, protein, and % of energy from protein for women in the DM trial 
comparison (control) group (DM-C), and for women in the WHI Observational Study 
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(OS).  The two cohorts will be used, separately and combined, to assess associations 
between calibrated nutrient consumption and cancer incidence as observed during WHI 
follow-up.  Cancer risk among DM intervention group women may depend in a complex 
manner on baseline and follow-up dietary patterns, so that intervention group women 
were excluded from the present analyses. 
 
MATERIALS AND METHODS 
Study cohorts 
Detailed accounts of design of the WHI Clinical Trial and Observational Study and of the 
DM trial findings have been presented (13-18).  This paper uses a subset of women 
assigned to the DM-C (n=29,294) and a subset of the OS cohort (n=93,676).  Both 
cohorts included only women who were 50-79 years old at recruitment, were 
postmenopausal, and had no medical condition associated with less than three years 
predicted survival.  Both provided common core questionnaires at baseline on medical 
history, reproductive history, family history, personal habits, psychosocial attributes, and 
food frequency (19, 20). 
 
DM trial women, who could be assigned to overlapping trials of postmenopausal 
hormone therapy, and of calcium and vitamin D supplementation, also satisfied 
additional exclusionary criteria.  To maximize commonality with the DM cohort, the 
76,987 OS women considered here were those remaining after imposing additional DM 
trial baseline exclusionary criteria as follows:  prior history of breast or colorectal cancer, 
or other cancer (except non-melanoma skin) within the preceding 10 years; a stroke or 
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myocardial infarction in the preceding six months; severe hypertension (systolic blood 
pressure >200 mm or diastolic blood pressure >105 mm); already following a low-fat 
diet; underweight (body mass index <18); or FFQ reported daily energy of <600 kcal or 
>5000 kcal).   
 
WHI food frequency questionnaire  
All DM trial and OS women completed FFQs at baseline.  DM trial women repeated the 
FFQ at one year following enrollment and approximately every three years thereafter, 
while OS women repeated the FFQ at three years following enrollment.  FFQs were 
provided in connection with visits to the 40 participating clinical centers, where 
completeness and quality control checks were applied.  The self-administered FFQ 
included 122 line items for individual foods/food groups, 19 adjustment items regarding 
fat intake, as well as summary questions, and the Nutrition Data System (Version 2005, 
University of Minnesota) was used to compute daily average nutrient consumption 
estimates (21, 22).   
 
Nutritional Biomarker Study 
The WHI Nutritional Biomarkers Study (NBS) was conducted in 2004-2005 to assess 
measurement properties of this FFQ and to produce calibrated consumption estimates 
for energy and protein.  The eligibility and recruitment methods for the NBS have been 
described (12).  544 representative women from the DM trial cohort were enrolled (276 
comparison group, 268 intervention group).  These weight-stable women participated in 
a doubly-labeled water protocol to estimate daily total energy expenditure over a two-
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week period, and a urinary nitrogen protocol to estimate daily protein consumption over 
a 24-hour period, and also provided a concurrent FFQ and other questionnaire data.  
Twenty percent (n=111) repeated the entire NBS protocol an average of six months 
later, to provide reliability data for measurement error component estimation (12).  FFQ 
total energy and protein were found to be underestimated while % of energy from 
protein was overestimated.  Women having high body mass index (BMI -- weight in 
kg/height in meters squared) and younger women underestimated energy consumption 
to a comparatively greater extent.  Calibration equations were developed for each of 
energy, protein, and % of energy from protein by linear regression of log-biomarker 
estimates on corresponding log-FFQ estimates, body mass index, age, ethnicity, and 
other factors (12).  For example, the calibrated log-energy consumption is given by 7.61 
+ 0.062 (log FFQ energy - 7.27) + 0.013 (BMI – 28.2) – 0.005 (age – 70.9 years), plus 
some less influential terms involving ethnicity, family income, and physical activity.  DM 
intervention group assignment did not meet inclusion criteria for any of the three 
calibration equations. 
 
NBS application to WHI cohorts 
Here we apply these calibration equations to FFQ data that were collected earlier in the 
WHI, and relate the calibrated consumption estimates to subsequent cancer incidence.  
Doing so is complicated by the use of the FFQ in participant screening for the DM trial.  
The exclusion of about 50% of women having baseline FFQ % of energy from fat <32, 
in conjunction with FFQ measurement error, implies that baseline FFQ % energy from 
fat is overestimated in the DM trial (by about 3% on average), with corresponding 
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estimates of energy likewise distorted.  OS baseline estimates are distorted in the 
opposite direction since many women screened out from the DM trial enrolled in the OS.  
In terms of Model B, these distortions arise because women tend to meet the FFQ 
inclusion criteria when the independent random error term (u) that attends a particular 
FFQ application is positive.  Later FFQs for a woman, following a sufficient period of 
time (e.g., 6 months) to avoid carry-over effects on this measurement component, can 
be expected to be free of this measurement effect.  Hence, our analyses rely on FFQs 
obtained at Year 1 in the DM-C, and at Year 3 in the OS, and only cancer diagnoses 
that follow these FFQ collections are included in analyses.  These FFQs were collected 
an average 6.5 years (DM-C) and 4 years (OS) prior to the NBS data collection. 
 
Dietary consumption and disease risk associations were estimated for total invasive 
cancer, as well as for invasive cancers of the breast, colon, rectum, ovary, 
endometrium, bladder, kidney, pancreas, and lung, and for lymphoma and leukemia.  
The ovarian cancer analyses were restricted to women without bilateral oophorectomy 
at baseline and the endometrial cancer analysis to women with uterus at baseline. 
 
DM women were queried twice per year, and OS women annually, concerning 
diagnosis of any cancer other than non-melanoma skin cancer.  Cancer reports were 
verified by medical record and pathology report review by centrally trained physician 
adjudicators at participating clinical centers (23).   
 
Statistical analyses 
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Log-consumption estimates were calibrated directly from the biomarker assessments 
(Model A) for the few women included in the NBS, and for other women using the 
calibration equations previously developed (12).   
 
Hazard ratio (HR) estimates were based on Cox regression (24).  Follow-up times 
extended from the Year 1 (DM-C) or Year 3 (OS) to the earliest of cancer occurrence, 
death, lost to follow-up, or March 31, 2005 when the intervention phase of WHI ended.  
To minimize mammographic screening influences on results, the breast cancer 
analyses censored the follow-up time for a woman the first time she exceeded two 
years without a mammogram.  The Cox model baseline hazard rates for each cancer 
outcome were stratified on baseline age in 5-year categories, and for the DM-C also on 
hormone therapy trial participation (active estrogen; estrogen placebo; active estrogen 
plus progestin; estrogen plus progestin placebo; not randomized).  Analyses that 
combine the two cohorts stratify also on cohort.  Analysis for specific cancer outcomes 
included standard risk factors in the Cox regression model to control confounding, as 
shown in Appendix Table A1.  Women having missing confounding factors were 
excluded from analysis. 
 
Principal analyses modeled the log-HR linearly on log-nutrient consumption, so that the 
HR for a fractional increase in the nutrient is independent of the consumption.  For 
display purposes, we present HRs for a 20% increase in consumption.  For a woman 
with median consumption, a 20% increment corresponds to about 413 kcal of energy, 
15 grams of protein, or 2.9 units in % of energy from protein.   
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Usual Cox model standard error estimates were calculated for uncalibrated 
consumption regression coefficients.  A more complex standard error estimation 
procedure is needed for the calibrated consumption coefficients to acknowledge 
uncertainty in the calibration parameter estimates, and in the ‘regression calibration’ HR 
estimation procedure (11), which has been shown to be free of practically important 
biases in extensive simulation studies.  A bootstrap procedure (500 bootstrap samples), 
with bootstrap sampling stratified on cohort, membership in the NBS and in the NBS 
reliability subset, was applied for calibrated standard error estimation.  A bootstrap 
procedure (500 samples) was also used to test equality of HRs in the DM-C and OS 
cohorts.   
 
Calibrated energy turns out to be strongly positively correlated with BMI.  The data 
analyzed here do not allow one to determine whether a high body mass should be 
regarded as a consequence of a high energy diet, in which case BMI should be 
excluded from the set of potential confounding factors to avoid overcorrection; or 
whether a high body mass may arise for other reasons (e.g., sedentary lifestyle), in 
which case energy consumption may be high as a result of related energy 
requirements, and BMI control would be needed in regression analyses.  Hence, we 
present HR estimates for energy and for BMI separately, and jointly.  Two-sided p-
values are used throughout. 
 
RESULTS 
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A total of 26,531 (91%) of DM-C women and 66,788 (87%) of OS women provided 
FFQs (Year 1 DM, Year 3 OS) and were without a prior cancer diagnosis during WHI 
follow-up.  Of these, 21,711 (82%) of DM-C and 59,105 (88%) of OS women had all 
data needed for energy calibration and for confounding control for total cancer.  Table 1 
shows some demographic and lifestyle characteristics for these women.  Analyses of 
other cancer outcomes or other nutrients involve a slightly different set of women, due 
to different confounding factors and, hence, missing data exclusions. 
 
Table 2 shows incidence rates and number of invasive cancers through March 31, 
2005, for calibrated energy analyses for each cancer site.  Incidence rates are similar 
between the two cohorts.  A total of 5041 invasive cancers contribute to the total cancer 
analyses, but the number of incident cancers is <300 for specific cancers other than 
breast, colon, endometrium, and lung. 
 
Table 3 shows the geometric mean consumption and 95% confidence interval for 
consumption of energy, protein, and % of energy from protein for both cohorts, with and 
without calibration.  The distribution of calibrated consumption estimates is similar in the 
two cohorts.  The narrower confidence intervals for the calibrated versus uncalibrated 
estimates reflect, in part, smaller variations in actual consumption compared to that 
assessed by the FFQ.   
 
Table 4 shows HR estimates for a 20% increase in total energy consumption under a 
linear log-HR model that excludes body mass index.  A 20% increase corresponds to 
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about two standard deviations for calibrated energy and % of energy from protein, and 
about 1.3 standard deviations for calibrated protein.  For comparison, extreme quartile 
medians differ by about 2.3 standard deviations and extreme tertile medians differ by 
about 1.9 standard deviations, for normally distributed exposures.   
 
Separate HR estimates (95% CIs) are given for the DM-C and OS cohorts, without and 
with biomarker calibration of consumption estimates.  Biomarker calibration clearly has 
a major impact on HR estimates, with evidence for positive associations between 
calibrated energy and total cancer, as well as certain site-specific cancers, in both the 
DM-C and OS cohorts, but with little evidence of association for uncalibrated energy.  
There is also little evidence of difference in HRs between the two cohorts, with or 
without calibration, with the possible exception of leukemia.   
 
The upper part of Figure 1 shows corresponding HR estimates and 95% confidence 
intervals from analysis of the two cohorts combined.  Calibrated energy is positively 
related to total (HR=1.18, 95% CI: 1.10, 1.27), breast (HR=1.24, 95% CI: 1.11, 1.38), 
colon (HR=1.35, 95% CI: 1.06, 1.71), endometrium (HR=1.83, 95% CI: 1.49, 2.25), and 
kidney cancer (HR=1.47, 95% CI: 1.00, 2.16), while uncalibrated energy was not 
significantly related to total cancer, or to any specific cancer, with the exception of an 
inverse association with colon cancer.  The wider confidence intervals for calibrated 
versus uncalibrated energy HRs reflects both uncertainty in the coefficients of the 
calibration equations, and de-attenuation that arises from acknowledging dietary 
assessment measurement error in the HR estimation procedure. 
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Analyses of calibrated protein and % of energy from protein similarly yielded little 
evidence of HR differences between the two cohorts (each P > 0.05).  The middle and 
lower panels of Figure 1 show corresponding combined cohort HRs and 95% 
confidence intervals for a 20% increase in these nutritional factors.  The HRs for a 20% 
increase in calibrated protein are above one for total cancer (HR=1.06, 95% CI: 1.01, 
1.12), breast cancer (HR=1.09, 95% CI: 1.01, 1.19), endometrial cancer (HR=1.37, 95% 
CI: 1.16, 1.61), and leukemia (HR=1.39, 95% CI: 1.05, 1.83).  These positive 
associations may be substantially attributable to correlation between protein and energy 
consumption, since the HR estimates for % energy from protein are less than one for 
total and most specific cancers, and the inverse association is significant for total cancer 
(HR=0.92, 95% CI: 0.85, 0.99 for a 20% increase in % of energy from protein).  Results 
corresponding to Figure 1 by quartile of calibrated consumption are given in Appendix 
Table A2.   
 
The correlation coefficients for BMI with log-transformed energy, protein and % of 
energy from protein in the combined cohorts were respectively 0.07, 0.10, and 0.07 
without calibration, and 0.81, 0.46, and -0.12 following calibration.  Hence, it may be 
difficult to distinguish between total energy and BMI associations, with total or site-
specific cancer.  Table 5 examines the effect of including BMI in the log-HR model on 
the calibrated energy HRs shown in Figure 1, and also shows the effect of including 
calibrated energy on the HR for BMI.  HRs for both energy and BMI are not significant 
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for most cancer sites and may be unstable, in the presence of the other variable, and 
CIs are wide. 
 
DISCUSSION 
This report has both methodologic and substantive implications:  On the methodology 
side, it provides a first application of the use of urinary recovery markers to correct for 
systematic bias in dietary self-report data, in an epidemiologic cohort setting.  In 
analyses that control for standard confounding factors, but not body mass index, FFQ 
estimates of energy, protein, or % of energy from protein were not significantly 
associated with total invasive cancer incidence.  In contrast, following biomarker 
calibration, the associations with total cancer incidence were strong for energy  
(P < 0.0001), moderate for protein (P = 0.01), and inverse for % of energy from protein 
(P = 0.03), suggesting that macronutrients other than protein drive the positive energy 
association.  Likewise, calibrated energy consumption was found to be positively 
associated with the risk of breast, colon, endometrium, and kidney cancer, whereas 
uncalibrated energy was not. 
 
These comparisons suggest that systematic bias in dietary assessment could have a 
profound effect on nutritional epidemiology findings.  Total energy assessment is a 
recognized weak aspect of FFQs.  Uncalibrated FFQs are generally believed to be more 
reliable for nutrient density than for absolute consumption estimates.  However, 
biomarker calibration also qualitatively affected the findings for protein density in relation 
to total cancer (Figure 1). 
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Measurement error has typically been acknowledged in epidemiology reporting through 
a simple de-attenuation factor, as befits measurement Model B in the absence of 
systematic bias (i.e., S2 = S3 = 0).  Such de-attenuation typically has little effect on 
significance levels.  The presence of systematic bias changes this feature, however, 
since regression coefficients are corrected for distortions beyond simple attenuation, 
possibly leading to substantially altered p-values. 
 
To help interpret the calibrated energy variable defined here, we note that calibrated 
energy can be viewed as estimated actual short-term energy consumption, as 
determined by FFQ energy, body mass index, age, and other factors.  The correlations 
of calibrated energy, on our combined cohorts, with log FFQ energy, body mass index, 
and age are respectively 0.35, 0.81, and -0.44.  The strong associations with age and 
especially with BMI imply that log FFQ energy does not adhere to a simple classical 
measurement model.  A linear regression of BMI on log-calibrated energy gives a 
projected BMI increase of 9.2 units corresponding to a 20% increase in calibrated 
energy suggesting, in conjunction with Table 5, that much of the observed dependence 
of cancer incidence rates on total energy can be explained by body mass associations 
with these diseases.  Table 5 likewise suggests that much of the dependence of cancer 
incidence rates on BMI can be explained by energy consumption associations with 
these diseases. 
 
17 
 
   
 
Our analyses yielded similar results when calibration equations were applied in the DM 
cohort where they were derived, and when exported to the OS.  However, this 
extrapolation is under near optimal conditions as the two cohorts were drawn from 
essentially the same populations, with much commonality in eligibility and exclusionary 
criteria.  Comparison with calibration equations from nutritional biomarker studies in 
other populations (e.g., 27, 28) could be informative. 
 
As noted above, the NBS was conducted in 2004-2005, an average of about 6.5 years 
after the 1-year FFQ data collection for the DM-C women, and about 4 years on 
average after the 3-year FFQ data collection for OS women.  Our application assumes 
that the calibration equations developed from NBS data apply to FFQs at these earlier 
time points.  Also, the biomarker data provide consumption estimates over a rather 
short period of time (e.g., six months between initial and repeat application in 20% 
subsample).  However, dietary patterns are expected to track over longer time periods 
for most women in these cohorts. 
 
On the substantive side, we observe strong positive associations between calibrated 
energy consumption and the risk of total and certain site-specific cancers.  There are 
also suggestions of a positive association between protein consumption and leukemia, 
and an inverse association between % of energy from protein and bladder cancer 
(Figure 1) that would be worth examining in other settings.  More comprehensive 
temporal data on the interplay between a high energy diet and body fat accumulation 
will be needed to understand mechanisms leading to elevated cancer risk with high 
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energy consumption.  However, whether body fat accumulation results from a history of 
high energy consumption, or whether a high body mass leads to increased energy 
requirements, or both, it is evident that a high BMI is an important aspect of total and 
site-specific cancer risk, and efforts to prevent obesity deserve a continued high priority 
in national cancer control efforts. 
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Figure Legend: 
Figure 1.  Estimated Hazard Ratios and 95% Confidence Intervals for a 20% Increase in 
Energy, Protein, or % of Energy from Protein Consumption, from Combined Analysis of 
Data from the Women’s Health Initiative Dietary Modification Trial Comparison Group 
(DM-C) and Observational Study (OS), Without and With Biomarker Calibration of 
Consumption:  Open box – uncalibrated, Black circle – calibrated; A) Energy, kcal/day; 
B) Protein, g/day; C) Percent of energy from protein. 
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Table 1.  Subject Characteristics for Women in the Women’s Health Initiative Dietary 
Modification Trial Comparison Group (DM-C) and Observational Study (OS). 
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Characteristic DM-C 
 (N=21711)† 
% (No.) 
OS 
(N=59105)†  
      % (No.) 
50-59 30 (6421) 19 (11135) 
60-69 48 (10495) 43 (25257) 
70-79 21 (4667) 35 (20555) 
Age (years)* 
80-89 1 (128) 4 (2158) 
Normal (<25.0) 26 (5704) 42 (24938) 
Overweight (25.0-29.9) 36 (7767) 34 (20361) 
BMI 
Obese (≥ 30) 38 (8239) 23 (13806) 
White 82 (17889) 86 (51028) 
Black 10 (2161) 6 (3661) 
Hispanic 3 (725) 3 (1736) 
Race 
Other* 4 (936) 5 (2680) 
< $20,000 15 (3218) 14 (8159) 
$20,000-$34,999 25 (5335) 23 (13605) 
$35,000-$49,999 21 (4593) 21 (12214) 
$50,000-$74,999 21 (4546) 21 (12407) 
Income (total yearly)     
$75,000+ 18 (4009) 22 (12720) 
< High school diploma 4 (893) 4 (2196) 
High school diploma/GED 18 (3803) 16 (9379) 
School after high school 40 (8593) 36 (21421) 
Education 
College degree or higher 39 (8422) 44 (26109) 
Current 6 (1392) 6 (3307) 
Past 52 (11373) 51 (30232) 
Smoking 
Never 41 (8946) 43 (25566) 
< 1.5 25 (5335) 16 (9508) 
1.5 – 6.2 25 (5378) 20 (11715) 
6.3 – 14.7 26 (5541) 27 (15708) 
Recreational 
Physical Activity 
(METs/week) 
> 14.8 25 (5457) 38 (22174) 
Breast cancer family 
history 
Yes 18 (3729) 19 (10631) 
Gail 5-year risk score < 1.00% 15 (3355) 11 (6778) 
 1.00-1.99% 62 (13368) 62 (36531) 
 2.00-2.99% 14 (3073) 16 (9623) 
 ≥ 3.00% 9 (1915) 10 (6173) 
29 
 
   
 
30 
 
 
Colon cancer family 
history 
yes 16 (3257) 17 (9006) 
History of polyps yes 8 (1780) 9 (5275) 
Unopposed Estrogen 
use ever 
yes 37 (8084) 38 (22736) 
Estrogen + 
Progesterone use 
ever 
yes 28 (6054) 31 (18395) 
Diabetes yes 6 (1313) 5 (2664) 
Hypertension yes 41 (8909) 37 (22029) 
Non drinker 10 (2086) 10 (6063) 
< 1 drink/week 36 (7708) 32 (18768) 
1-7 drinks/week 27 (5923) 27 (16048) 
7+ drinks/week 10 (2116) 14 (8010) 
Alcohol use  
Past drinker 18 (3878) 17 (10216) 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Age at FFQ measurement (Year 1 DM-C and Year 3 OS) 
†Number of subjects for whom there were no missing values for the energy regression calibration or for total 
cancer hazard ratio analysis.
   
 
Table 2.  Incidence of Invasive Cancer in the Women’s Health Initiative Dietary 
Modification Trial Comparison Group (DM-C) and Observational Study (OS) Following 
Year 1 (DM-C) and Year 3 (OS) Food Frequency Data Collection.                      
 Incidence per 1000 person-years (number of cases) 
Cancer Site DM-C 
(N=21711)† 
OS 
(N=59105) † 
Total 
(N=80816) † 
Total Cancer* 12.34 (1807) 11.06 (3234) 11.48 (5041) 
Breast 4.98 (685) 4.73 (1018) 4.83 (1703) 
Colon 0.89 (123) 0.87 (240) 0.88 (363) 
Rectum 0.33 (47) 0.14 (40) 0.21 (87) 
Ovary 0.63 (72) 0.57 (131) 0.59 (203) 
Endometrium 1.32 (115) 1.21 (220) 1.25 (335) 
Bladder 0.25 (39) 0.20 (60) 0.22 (99) 
Kidney 0.28 (42) 0.27 (81) 0.27 (123) 
Pancreas 0.26 (40) 0.23 (71) 0.24 (111) 
Lung 0.95 (146) 0.91 (275) 0.92 (421) 
Lymphoma 0.57 (88) 0.57 (175) 0.57 (263) 
Leukemia 0.32 (49) 0.20 (60) 0.24 (109) 
 
*Exclusive of non-melanoma skin cancer 
†The number of subjects in the cohort for whom there were no missing values for the energy 
calibration or for total cancer hazard ratio analysis.  The number of subjects with no missing 
values varied slightly by cancer site and nutrient. 
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Table 3.  Geometric Mean Consumption and 95% Confidence Intervals for Uncalibrated 
Dietary Consumption as Estimated by the Women’s Health Initiative (WHI) Food 
Frequency Questionnaire, and for Calibrated Consumption Using Nutritional Biomarker 
Data, in the WHI Dietary Modification Trial Comparison Group (DM-C) and 
Observational Study (OS). 
 
 Geometric Mean (95 % Confidence Interval) 
 Energy (kcal/day) Protein (g/day) % of Energy from Protein
 Uncalibrated Calibrated* Uncalibrated Calibrated Uncalibrated Calibrated 
DM-C 
(N=21,711) 
1477.2  
(676.6, 3224.9)  
 2140.6 
(1786.9, 2564.2)
61.2  
(26.3, 142.1)  
78.1 
(58.4,104.4) 
16.6  
(11.5, 24.0)  
14.4  
(11.9, 17.3) 
OS 
(N=59,105) 
1384.3  
(641.0, 2989.4)  
 2055.8  
(1722.3, 2453.9) 
58.6  
(24.8, 138.1)  
74.2  
(54.8, 100.5) 
16.9 
 (11.5, 25.0)  
14.4  
(11.8, 17.6) 
 
 
*Calibrated using measurement model A for women in the Nutrition Biomarker Study, and model 
B otherwise. 
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Table 4.  Hazard Ratio (HR) Estimates for a 20% Increase in Energy (kcal/day) 
Consumption in the WHI Dietary Modification Trial Comparison Group (DM-C) and the 
WHI Observational Study (OS), Without and With Biomarker Calibration. 
 
 
 
DM-C 
 
OS 
 
Test of Equality 
of HRs 
 
Cancer Site 
Uncalibrated 
HR*  
(95%CI) 
Calibrated  
HR* 
(95%CI)† 
Uncalibrated 
HR* 
 (95%CI) 
Calibrated  
HR* 
(95%CI)† 
Uncalibrated 
P-value‡ 
Calibrated  
P-value‡ 
 
Total Cancer 
1.00 
(0.98,1.02) 
1.13 
(1.02,1.26) 
1.01 
(0.99,1.03)  
1.21  
(1.11,1.32) 
 0.52 
  
0.30 
 
Breast  0.99  
(0.95,1.02) 
1.25 
(1.07,1.47) 
1.02 
(0.99,1.05) 
1.23 
(1.06,1.41) 0.20 0.85 
Colon 0.93 
(0.86,1.00) 
1.11 
(0.75,1.66) 
0.96 
(0.91,1.02) 
1.47 
(1.11,1.94) 0.44 0.26 
Rectum 1.10 
(0.96,1.26) 
1.00 
(0.49,2.02) 
1.00 
(0.87,1.14) 
1.52 
(0.94,2.47) 0.30 0.34 
Ovary 0.98 
(0.89,1.09) 
1.00 
(0.61,1.63) 
1.04 
(0.96,1.12) 
1.09 
(0.71,1.65) 0.42 0.80 
Endometrium 1.00 
(0.92,1.09) 
1.73 
(1.21,2.49) 
1.07 
(1.00,1.14) 
1.88 
(1.48,2.39) 0.21 0.69 
Bladder 0.99 
(0.87,1.13) 
1.07 
(0.58,1.97) 
1.10 
(0.98,1.23) 
1.27 
(0.82,1.97) 0.26 0.70 
Kidney 1.14 
(1.00,1.30) 
1.87 
(0.95,3.68) 
1.00 
(0.90,1.11) 
1.28 
(0.81,2.05) 0.11 0.42 
Pancreas 1.02 
(0.90,1.16) 
1.72 
(1.09,2.73) 
1.01 
(0.91,1.12) 
1.02 
(0.49,2.10) 0.88 0.22 
Lung 0.99 
(0.93,1.06) 
1.01 
(0.72,1.42) 
0.97 
(0.93,1.03) 
0.76 
(0.55,1.06) 0.73 0.26 
Lymphoma 0.96 
(0.88,1.04) 
0.75 
(0.47,1.23) 
0.98 
(0.92,1.05) 
0.75 
(0.53,1.08) 0.69 0.97 
Leukemia 0.97 
(0.86,1.10) 
0.90 
(0.52,1.56) 
1.14 
(1.01,1.28) 
1.93 
(1.15,3.21) 0.07 0.05 
 
*Hazard ratio associated with a 20% increase in daily consumption by considering hazard ratio for 
log(1.2x) compared to log(x): exp(beta)log 1.2 where beta is estimated coefficient in Cox regression. 
 
†95% Confidence intervals for calibrated HRs are based on log-estimated HR ± 1.96 x bootstrap standard 
error. 
 
‡P-value based on difference between log-HRs from DM-C and OS cohorts, with bootstrap estimate of 
standard deviation for the difference between the calibrated log-HRs. 
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Table 5.  Hazard Ratio (HR) Estimates for a 20% Increase in Calibrated Energy 
(kcal/day) Consumption and for a 10-unit Increase in Body Mass Index (BMI), in 
Analyses that Either Exclude (Unadjusted) or Include (Adjusted) the Other Variable, 
Using Data from WHI Dietary Modification Trial Comparison Group and Observational 
Study.  
 
  
Calibrated Energy 
 
BMI 
 
Cancer Site 
BMI Unadjusted 
HR 
 (95%CI)* 
BMI Adjusted  
HR  
(95%CI)* 
Energy Unadjusted 
HR 
 (95%CI) 
Energy Adjusted 
HR 
(95%CI)* 
Total Cancer 1.18 (1.10,1.27)  0.90 (0.76,1.06) 1.17 (1.12,1.23)  1.27 (1.11,1.44)  
Breast  1.24 (1.11,1.38) 1.11 (0.81,1.53) 1.20 (1.10,1.30)  1.10 (0.86,1.40)  
Colon 1.35 (1.06,1.71) 0.70 (0.41,1.18) 1.36 (1.16,1.61)  1.81 (1.19,2.76)  
Rectum 1.23 (0.79,1.91) 2.09 (0.67,6.50) 1.15 (0.81,1.63)  0.62 (0.26,1.52)  
Ovary 1.05 (0.76,1.45) 1.12 (0.61,2.04) 1.00 (0.79,1.28)  0.95 (0.58,1.56)  
Endometrium 1.83 (1.49,2.25) 1.40 (0.83,2.35) 1.60 (1.37,1.87)  1.26 (0.84,1.88)  
Bladder 1.18 (0.83,1.68) 1.64 (0.63,4.25) 1.08 (0.77,1.51)  0.74 (0.34,1.60)  
Kidney 1.47 (1.00,2.16) 1.27 (0.52,3.11) 1.41 (1.08,1.83)  1.14 (0.59,2.20)  
Pancreas 1.26 (0.78,2.03) 0.88 (0.41,1.91) 1.17 (0.86,1.59)  1.37 (0.76,2.50)  
Lung 0.85 (0.67,1.08) 0.58 (0.37,0.92) 0.98 (0.83,1.16)  1.44 (0.99,2.11)  
Lymphoma 0.75 (0.56,1.02) 0.60 (0.34,1.04) 0.87 (0.70,1.08)  1.26 (0.83,1.90)  
Leukemia 1.41 (0.93,2.14) 1.88 (0.76,4.60) 1.22 (0.90,1.65)  0.78 (0.40,1.51)  
 
*95% confidence intervals for analyses that include calibrated energy are based on log-estimated HR 
±1.96 x bootstrap standard error. 
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Figure 1.  
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Appendix Table A1.  Factors Included in Cox Model Hazard Ratio Analyses to Control 
Confounding, for Each Cancer Outcome.  (The same factors were used for the Dietary 
Modification comparison group (DM-C) and Observational Study (OS) cohorts.) 
Cancer Site  Total  
Cancer 
Breast Colon 
Rectum
Ovary Endo- 
metrium
Bladder 
Kidney 
Pancreas 
Lung 
Lymphoma
Leukemia 
Race* (white/other, 
black, Hispanic) 
x x x†  x x§  
Education (high 
school or less, 
beyond H.S, 
college degree) 
x x       
Exercise 
(METs/week) 
x x x     
Smoking* (never, 
past, current) 
x x   x   x  x¶ 
Alcohol* (never, 
past, <1/wk, 1-7/wk, 
>7/wk) 
x x   x   x  
Breast cancer 
family history  
(no, yes) 
 x  x    
Gail 5-yr risk (5-yr 
absolute risk %) 
 x      
Unopposed 
Estrogen use ever  
(no, yes) 
x x  x† x x   
Estrogen plus 
Progesterone 
use ever (no, yes) 
x x  x† x x   
Colon cancer 
family history  
(no, yes) 
  x     
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 Appendix Table A1 (continued). 
 
Cancer Site 
 
Total  
Cancer 
 
Breast
 
Colon 
Rectum
 
Ovary
 
Endo- 
metrium
 
Bladder 
Kidney 
Pancreas 
Lung 
 
 
Lymphoma
Leukemia 
History of colorectal 
polyps (no, yes) 
 
    x†         
History of diabetes 
(no, yes) 
 
x          
Hypertension (no, 
yes) 
 
x      x x‡  
 
 
*For rare cancers: race: black/Hispanic (yes/no); smoking: ever (yes/no); alcohol: nondrinker (past/never), 
light drinker (<1 drink/wk), moderate/heavy (1+ drinks/wk).  
 
†Colon cancer only 
 
§Lung only  
 
‡Kidney only 
 
¶Leukemia only 
 
 
   
 
Appendix Table A2.  Hazard Ratios by Quartile of Biomarker-calibrated Nutrition Consumption from the Analyses of 
Combined Data from the WHI Dietary Modification Trial Comparison Group (DM-C) and Observational Study (OS). 
 
 
 
 
Energy (kcal/day) 
HR (95% CI)* 
 
Protein (g/day) 
HR (95% CI)* 
 
% of Energy from Protein 
HR (95% CI)* 
 
Cancer Site 
 
Quartile 2 
 
Quartile 3 
 
Quartile 4 
 
Quartile 2 
 
Quartile 3 
 
Quartile 4 
 
Quartile 2 
 
Quartile 3 
 
Quartile 4 
 
Total Cancer 1.07 
(0.97, 1.17) 
 
1.07 
(0.97, 1.19) 
1.18 
(1.07, 1.31) 
 
1.07 
(0.97, 1.18) 
1.10 
(0.99, 1.22) 
 
1.09 
(0.98, 1.22) 
0.94 
(0.85,1.04)  
0.94 
(0.85,1.04) 
0.92 
(0.82,1.04) 
Breast  1.07 
(0.90, 1.28) 
1.17 
(0.98, 1.40) 
1.33 
(1.12, 1.58) 
1.15 
(0.97, 1.36) 
1.07 
(0.90, 1.28) 
1.22 
(0.99, 1.49) 
0.97 
(0.83,1.13)  
0.92 
(0.78,1.09) 
0.94 
(0.78,1.12) 
Colon 1.27 
(0.88, 1.85) 
1.12 
(0.78, 1.60) 
1.51 
(1.03, 2.21) 
0.97 
(0.70, 1.34) 
1.11 
(0.76, 1.61) 
0.96 
(0.64, 1.44) 
0.83 
(0.58,1.2)  
0.98 
(0.71,1.35) 
1.06 
(0.74,1.51) 
Rectum 1.82 
(0.81, 4.08) 
2.34 
(1.04, 5.26) 
1.51 
(0.64, 3.58) 
1.22 
(0.56, 2.65) 
1.57 
(0.72, 3.41) 
1.08 
(0.48, 2.41) 
0.85 
(0.43,1.67)  
1.24 
(0.63,2.44) 
1.01 
(0.52,1.96) 
Ovary 1.23 
(0.78, 1.93) 
1.19 
(0.75, 1.89) 
0.91 
(0.58, 1.43) 
0.68 
(0.42, 1.10) 
1.10 
(0.73, 1.66) 
0.85 
(0.55, 1.31) 
1.16 
(0.76,1.77)  
1.13 
(0.72,1.8)  
1.08 
(0.69,1.69) 
Endometrium 1.02 
(0.66, 1.57) 
1.26 
(0.81, 1.96) 
2.03 
(1.38, 3.00) 
1.36 
(0.91, 2.04) 
1.59 
(1.08, 2.35) 
1.85 
(1.26, 2.70) 
0.92 
(0.65,1.29)  
0.99 
(0.71,1.39) 
0.92 
(0.63,1.35) 
Bladder 1.76 
(0.89, 3.46) 
2.14 
(1.02, 4.51) 
1.05 
(0.47, 2.39) 
1.11 
(0.54, 2.28) 
1.25 
(0.64, 2.45) 
0.96 
(0.45, 2.05) 
0.72 
(0.39,1.33)  
0.84 
(0.44,1.58) 
0.58 
(0.28,1.22) 
Kidney 1.42 
(0.77, 2.62) 
1.31 
(0.71, 2.43) 
1.44 
(0.80, 2.61) 
1.12 
(0.62, 2.03) 
0.98 
(0.53, 1.80) 
1.31 
(0.73, 2.36) 
0.8 
(0.44,1.48)  
1.1 
(0.63,1.92) 
0.86 
(0.48,1.53) 
Pancreas 0.94 
(0.49, 1.79) 
1.24 
(0.67, 2.32) 
1.33 
(0.68, 2.60) 
1.41 
(0.82, 2.41) 
0.95 
(0.47, 1.92) 
1.19 
(0.60, 2.37) 
0.89 
(0.54,1.44)  
0.65 
(0.36,1.17) 
0.92 
(0.56,1.53) 
Lung 0.90 
(0.68, 1.19) 
0.75 
(0.53, 1.07) 
0.79 
(0.58, 1.08) 
1.00 
(0.75, 1.34) 
1.05 
(0.76, 1.43) 
0.78 
(0.55, 1.10) 
0.99 
(0.73,1.33)  
0.9 
(0.66,1.23) 
0.92 
(0.67,1.26) 
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Appendix Table A2 (continued). 
 
 
 
Energy (kcal/day) 
HR (95% CI)* 
 
Protein (g/day) 
HR (95% CI)* 
 
% of Energy from Protein 
HR (95% CI)* 
 
Cancer Site 
 
Quartile 2 
 
Quartile 3 
 
Quartile 4 
 
Quartile 2 
 
Quartile 3 
 
Quartile 4 
 
Quartile 2 
 
Quartile 3 
 
Quartile 4 
Lymphoma 0.99 
(0.70, 1.42) 
0.81 
(0.54, 1.21) 
0.66 
(0.42, 1.03) 
0.88 
(0.59, 1.30) 
0.96 
(0.63, 1.44) 
0.68 
(0.41, 1.11) 
1.11 
(0.77,1.59)  
0.89 
(0.61,1.28) 
0.93 
(0.61,1.4)  
Leukemia 1.46 
(0.71, 3.03) 
1.63 
(0.84, 3.18) 
1.46 
(0.69, 3.10) 
1.38 
(0.64, 2.99) 
2.05 
(1.02, 4.09) 
1.77 
(0.82, 3.81) 
1.29 
(0.74,2.24)  
1.28 
(0.73,2.25) 
1.39 
(0.76,2.54) 
 
 
*Estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for second, third, and fourth quartiles relative to the first of biomarker-
calibrated nutrient consumption.  Confidence intervals for log-HRs derive from log-HR estimate ±1.96 times the corresponding bootstrapped 
standard deviation estimate. 
 
 
 
